EUVIMEDEUVIMED entdecken
Crossref

Reporting atrial fibrillation with bispecific T-cell engagers in the Food and Drug Administration Adverse Event Reporting System

Brian Portela

NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026

DOI: 10.67209/asdr9241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Brian Portela. Die Arbeit nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, institutions have transitioned the use of bispecific T-cell engagers (BTCEs) from the inpatient to outpatient setting, using step-up dosing strategies and monitoring protocols. BTCE therapies activate cytotoxic T cells and promote cytokine release, which may contribute to atrial fibrillation (AF) by inducing inflammation that alters atrial electrophysiology, disrupts autonomic regulation, and facilitates atrial arrhythmogenesis. AF has been reported with other immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies and immune checkpoint inhibitors. Despite biological plausibility, the atrial arrhythmic risk of BTCE therapies has not been well characterized in post-marketing studies. This study sought to determine whether AF was reported at a disproportionately higher frequency in association with BTCE therapies compared with other drugs in the United States Food and Drug Administration Adverse Event Reporting System (FAERS).

Zitieren

APA

Portela, B. (2026). Reporting atrial fibrillation with bispecific T-cell engagers in the Food and Drug Administration Adverse Event Reporting System. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/asdr9241

Vancouver

Portela B. Reporting atrial fibrillation with bispecific T-cell engagers in the Food and Drug Administration Adverse Event Reporting System. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/asdr9241

BibTeX
@article{Portela2026,
  author = {Portela, Brian},
  title = {Reporting atrial fibrillation with bispecific T-cell engagers in the Food and Drug Administration Adverse Event Reporting System},
  journal = {NCODA Oncology and Hematology Meeting Abstracts},
  year = {2026},
  doi = {10.67209/asdr9241}
}
Kostenlos starten →